12.13.25 -- Bioprocess Online Best Of November

Bristol Myers Squibb's high-throughput stable CHO platform produces high-titer, high-quality material in a fraction of the conventional timeline.

Here's a blueprint for transforming the fragmented, high-risk interface between vector and cell therapy platforms into a unified, predictable, and compliant system.

In this segment from the Bioprocess Online Live event, “Aligning CMC And MSAT To Move PATs Out Of Pilot Mode,” our panelists emphasize the importance of strategic planning for PAT implementation and the value of cross-training. Mengyao Li, Ph.D., from Novartis suggests taking a stage-gated approach and starting with the “low-hanging fruit.”

Regular preventive maintenance is essential for ensuring the longevity and optimal performance of your shaking incubator. Find out how this approach helps avoid costly downtime and protects your research.

Perfusion-based upstream production offers up to 24% lower cost and significantly higher productivity than fed-batch, enabling faster timelines, better facility utilization, and improved quality.

This resource provides a clear roadmap for delivering advanced sterile injectable therapies with confidence, meeting both regulatory demands and patient needs without compromise.